Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis
Background: Monoamine oxidases (MAOs) were discovered nearly a century ago. This article aims to analyze the research literature landscape associated with MAOs as privileged class of neuronal enzymes (neuroenzymes) with key functions in the processes of neurodegeneration, serving as important biolog...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-05-01
|
| Series: | Frontiers in Molecular Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fnmol.2019.00143/full |
| _version_ | 1818408667274280960 |
|---|---|
| author | Andy Wai Kan Yeung Maya G. Georgieva Atanas G. Atanasov Atanas G. Atanasov Nikolay T. Tzvetkov |
| author_facet | Andy Wai Kan Yeung Maya G. Georgieva Atanas G. Atanasov Atanas G. Atanasov Nikolay T. Tzvetkov |
| author_sort | Andy Wai Kan Yeung |
| collection | DOAJ |
| description | Background: Monoamine oxidases (MAOs) were discovered nearly a century ago. This article aims to analyze the research literature landscape associated with MAOs as privileged class of neuronal enzymes (neuroenzymes) with key functions in the processes of neurodegeneration, serving as important biological targets in neuroscience. With the accumulating publications on this topic, we aimed to evaluate the publication and citation performance of the contributors, reveal the popular research themes, and identify its historical roots.Methods: The electronic database of Web of Science (WoS) Core Collection was searched to identify publications related to MAOs, which were analyzed according to their publication year, authorship, institutions, countries/regions, journal title, WoS category, total citation count, and publication type. VOSviewer was utilized to visualize the citation patterns of the words appearing in the titles and abstracts, and author keywords. CRExplorer was utilized to identify seminal references cited by the MAO publications.Results: The literature analysis was based on 19,854 publications. Most of them were original articles (n = 15,148, 76.3%) and reviews (n = 2,039, 10.3%). The top five WoS categories of the analyzed MAO publications were Pharmacology/Pharmacy (n = 4,664, 23.5%), Neurosciences (n = 4,416, 22.2%), Psychiatry (n = 2,906, 14.6%), Biochemistry/Molecular Biology (n = 2,691, 13.6%), and Clinical Neurology (n = 1,754, 8.8%). The top 10 institutions are scattered in the United States, UK, France, Sweden, Canada, Israel, and Russia, while the top 10 countries/regions with the most intensive research on the field of MAOs are the United States, followed by European and Asian countries. More highly cited publications generally involved neurotransmitters, such as dopamine (DA), serotonin, and norepinephrine (NE), as well as the MAO-A inhibitors moclobemide and clorgyline, and the irreversible MAO-B inhibitors selegiline and rasagiline.Conclusion: Through decades of research, the literature has accumulated many publications investigating the therapeutic effects of MAO inhibitors (MAOIs) on various neurological conditions, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and depression. We envision that MAO literature will continue to grow steadily, with more new therapeutic candidates being tested for better management of neurological conditions, in particular, with the development of multi-target acting drugs against neurodegenerative diseases. |
| first_indexed | 2024-12-14T09:47:22Z |
| format | Article |
| id | doaj.art-a1ad03c0aed04684a704d1b50403594a |
| institution | Directory Open Access Journal |
| issn | 1662-5099 |
| language | English |
| last_indexed | 2024-12-14T09:47:22Z |
| publishDate | 2019-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Neuroscience |
| spelling | doaj.art-a1ad03c0aed04684a704d1b50403594a2022-12-21T23:07:36ZengFrontiers Media S.A.Frontiers in Molecular Neuroscience1662-50992019-05-011210.3389/fnmol.2019.00143464380Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature AnalysisAndy Wai Kan Yeung0Maya G. Georgieva1Atanas G. Atanasov2Atanas G. Atanasov3Nikolay T. Tzvetkov4Oral and Maxillofacial Radiology, Applied Oral Sciences, Faculty of Dentistry, The University of Hong Kong, Hong Kong, ChinaDepartment of Biochemical Pharmacology and Drug Design, Institute of Molecular Biology Roumen Tsanev, Bulgarian Academy of Sciences, Sofia, BulgariaThe Institute of Genetics and Animal Breeding, Polish Academy of Sciences, Magdalenka, PolandDepartment of Pharmacognosy, University of Vienna, Vienna, AustriaDepartment of Biochemical Pharmacology and Drug Design, Institute of Molecular Biology Roumen Tsanev, Bulgarian Academy of Sciences, Sofia, BulgariaBackground: Monoamine oxidases (MAOs) were discovered nearly a century ago. This article aims to analyze the research literature landscape associated with MAOs as privileged class of neuronal enzymes (neuroenzymes) with key functions in the processes of neurodegeneration, serving as important biological targets in neuroscience. With the accumulating publications on this topic, we aimed to evaluate the publication and citation performance of the contributors, reveal the popular research themes, and identify its historical roots.Methods: The electronic database of Web of Science (WoS) Core Collection was searched to identify publications related to MAOs, which were analyzed according to their publication year, authorship, institutions, countries/regions, journal title, WoS category, total citation count, and publication type. VOSviewer was utilized to visualize the citation patterns of the words appearing in the titles and abstracts, and author keywords. CRExplorer was utilized to identify seminal references cited by the MAO publications.Results: The literature analysis was based on 19,854 publications. Most of them were original articles (n = 15,148, 76.3%) and reviews (n = 2,039, 10.3%). The top five WoS categories of the analyzed MAO publications were Pharmacology/Pharmacy (n = 4,664, 23.5%), Neurosciences (n = 4,416, 22.2%), Psychiatry (n = 2,906, 14.6%), Biochemistry/Molecular Biology (n = 2,691, 13.6%), and Clinical Neurology (n = 1,754, 8.8%). The top 10 institutions are scattered in the United States, UK, France, Sweden, Canada, Israel, and Russia, while the top 10 countries/regions with the most intensive research on the field of MAOs are the United States, followed by European and Asian countries. More highly cited publications generally involved neurotransmitters, such as dopamine (DA), serotonin, and norepinephrine (NE), as well as the MAO-A inhibitors moclobemide and clorgyline, and the irreversible MAO-B inhibitors selegiline and rasagiline.Conclusion: Through decades of research, the literature has accumulated many publications investigating the therapeutic effects of MAO inhibitors (MAOIs) on various neurological conditions, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and depression. We envision that MAO literature will continue to grow steadily, with more new therapeutic candidates being tested for better management of neurological conditions, in particular, with the development of multi-target acting drugs against neurodegenerative diseases.https://www.frontiersin.org/article/10.3389/fnmol.2019.00143/fullmolecular neurosciencemonoamine oxidasetyraminebibliometricshistoryAlzheimer’s disease |
| spellingShingle | Andy Wai Kan Yeung Maya G. Georgieva Atanas G. Atanasov Atanas G. Atanasov Nikolay T. Tzvetkov Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis Frontiers in Molecular Neuroscience molecular neuroscience monoamine oxidase tyramine bibliometrics history Alzheimer’s disease |
| title | Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis |
| title_full | Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis |
| title_fullStr | Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis |
| title_full_unstemmed | Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis |
| title_short | Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis |
| title_sort | monoamine oxidases maos as privileged molecular targets in neuroscience research literature analysis |
| topic | molecular neuroscience monoamine oxidase tyramine bibliometrics history Alzheimer’s disease |
| url | https://www.frontiersin.org/article/10.3389/fnmol.2019.00143/full |
| work_keys_str_mv | AT andywaikanyeung monoamineoxidasesmaosasprivilegedmoleculartargetsinneuroscienceresearchliteratureanalysis AT mayaggeorgieva monoamineoxidasesmaosasprivilegedmoleculartargetsinneuroscienceresearchliteratureanalysis AT atanasgatanasov monoamineoxidasesmaosasprivilegedmoleculartargetsinneuroscienceresearchliteratureanalysis AT atanasgatanasov monoamineoxidasesmaosasprivilegedmoleculartargetsinneuroscienceresearchliteratureanalysis AT nikolayttzvetkov monoamineoxidasesmaosasprivilegedmoleculartargetsinneuroscienceresearchliteratureanalysis |